





The International Network on
Hepatitis in Substance Users (INHSU)

Annual Report 2019 / 2020

Working together to improve the health of people who use drugs




Connecting with Care project, Toronto.



Connecting with Care project, Montreal.

Contents

INHSU at a glance	03	Strategic planning	14
About INHSU	04	The 8th International Conference on Hepatitis Care in Substance Users	15
President's report	06	INHSU Africa	16
Board of directors	09	Hepatitis C in primary care and drug and alcohol settings education program	17
Our members	12	Advocacy efforts	19
INHSU Prisons and INHSU Committees	13	2019/2020 financial report	20



51
countries

10 Board members

419
practitioners trained

01
Special Interest Group,
INHSU Prisons

05

Advocacy films including;

02

Global Hepatitis Elimination Film Awards

03

Innovation Awards given, recognising excellent models of care that enhance HCV care in people who use drugs

INHSU is a global network dedicated to improving the health of people who use drugs. With a focus on hepatitis C and other infectious diseases we focus our services on three key areas; **knowledge exchange, education and advocacy.**

About INHSU

The International Network on Hepatitis in Substance Users (INHSU) is a global network of people dedicated to improving the health and wellbeing of people who use drugs, with a specific focus on infectious diseases.

What we do

We connect experts and advocates across the world to share knowledge, educate communities, and develop evidence-based policy responses to improve the health of people who use drugs.

We concentrate our activities in three focus areas:



Knowledge Exchange

We bring together global experts – senior and emerging – across a range of professional areas to share knowledge on good practice. We focus on research that seeks to improve access to prevention, treatment, and care for infectious diseases (with a key focus on hepatitis C) and drug-related harms for people who use drugs.



Education

In partnership with the Australasian Society for HIV, Sexual Health and Viral Hepatitis Medicine (ASHM), we educate health care providers, program managers, harm reduction experts, researchers, and policymakers in order to improve their knowledge, confidence and skills around key issues.



Advocacy

We work with our international partners to develop evidence-based calls to action and encourage decision makers to implement proven interventions that improve the health of people who use drugs in local communities, countries, regions and globally.

Our vision

A world where people who use drugs have access to evidence-based services, treatments, and support needed to improve health and live well.

Delegates at INHSU
2019, Montreal, Canada.

Our values

As a values-based organisation, how we do things is as important as what we do. The values that drive our engagement with members, stakeholders, partners and suppliers are:

- **Integrity:** We act with trust, honesty, and fairness
- **Excellence:** We strive to reflect good practice in everything we do
- **Innovation:** We encourage and showcase new ways of thinking
- **Collaboration:** We know we can accomplish more when we all work together

TB HIV Care's Clean Up Crew in down-town Cape Town.
Image taken during INHSU Africa 2020.

- **Respect:** We value the input of everyone, everywhere working in – or affected by – drug use, hepatitis C, and other infectious diseases
- **People-first:** We ensure that people who use drugs are equal partners in the development and implementation of services focused on improving their health



President's report

Jason Grebely,
INHSU PRESIDENT



The last year has been one like no other for all of us. While there have been many highlights, it is impossible to ignore the impact of the global COVID-19 pandemic that we have all be grappling with since its emergence in early 2020. This has seen significant disruption to everyone's plans and it has had a disproportionate impact on the community we serve – people who use drugs. Across the world, members of INHSU have been at the front line of responding to COVID-19. As we move into a new phase of working out how to live with COVID-19, we will need to adapt our ways of working to ensure that we continue our shared focus on improving the lives of people who use drugs.

A new direction for INHSU

We celebrated our first decade of operations in 2019, and we used this milestone as an opportunity to

reflect on our strategic directions for our future work. We are delighted to present our new strategic plan within this report. We thank everyone who so generously engaged in this process – almost 200 members, partners and stakeholders through a stakeholder survey, focus groups and individual interviews. I would also like to thank Rebecca Vassarotti for her tireless efforts in conducting interviews and synthesizing this information. Key outcomes include:

- The decision to add the word 'health' to our name, with the organisation now being known as the International Network on Health and Hepatitis in Substance Users. Our logo and acronym will remain the same, but we believe it is important to reflect the strong feedback from members and stakeholders that we broaden our focus



Jason Grebely,
INHSU PRESIDENT

“We will need to adapt our ways of working to ensure that we continue our shared focus on improving the lives of people who use drugs.”

President's report

Jason Grebely,
INHSU PRESIDENT

- The broadening of our focus to improving the health of people who use drugs. While we will continue to spotlight key issues around hepatitis and infectious diseases, we recognise the need to engage in a way that is holistic and people-centred
- Specific work to engage with communities in low and middle-income settings
- Continuing to engage in the areas of knowledge exchange, education and advocacy

Growing the INHSU conference portfolio

The annual conference continues to be a key activity for the organisation, and in September 2019, over 700 delegates came together in Montreal. Members and partners continue to provide extremely positive feedback around the value of the conference

– both in terms of high-quality scientific exchange, as well as an opportunity to nurture professional collaboration and networks.

Education continues to be a significant part of our work.

Through 2019/2020 we delivered education to 419 participants across Canada, France, Germany, Italy, Sweden and Switzerland in partnership with the Australasian Society for HIV, Sexual Health and Viral Hepatitis Medicine.

In February 2020, we were delighted to hold our very first regional meeting, INHSU Africa 2020. The event was held in Cape Town, with around 200 delegates from 10 countries in the African region and international partners. This provided us with an opportunity to develop

new relationships and partnerships, and explore the role that INHSU can play in supporting work in resource-constrained settings. It also provided another opportunity to work with international partners including TB HIV Care (the in-country host), Open Society Foundations and Frontline AIDS. We are excited to continue engagement with the many delegates who attended INHSU Africa 2020, including specific projects in South Africa and Kenya.

Introducing Connecting with Care

2019/2020 also saw the initial phase of our Connecting with Care project commence, initially focusing on the development of digital stories to highlight successful models of care throughout Canada. This project was undertaken in partnership with Canadian partners CATIE and CanHepC.

INHSU Africa 2020.



President's report

Jason Grebely,
INHSU PRESIDENT

We also delivered a film project in [South Africa](#). We were humbled and excited by the news that [Connecting with Care Ahtahkakoop](#) was awarded the overall grand prize in the Coalition for Global Hepatitis Elimination's First Annual Hepatitis Elimination Video Contest. Connecting with Care South Africa was awarded first prize in the Political and Civil Support category and Connecting with Care [Montreal](#) and Connecting with Care [Toronto](#) were also given honourable mentions.

Planning is underway for similar digital story projects in Australia and Europe. In addition, the Connecting with Care Project will include the development of an interactive toolkit for practitioners and policy makers and the highlighting of models of care in different community settings.

Jason Grebely,
INHSU PRESIDENT

INHSU 2019, Montreal, Canada.



A heartfelt thank you

As is the case every year, it is not possible for the organisation to deliver the scope of work without the dedication and commitment of a wide range of people. I would like to thank my Board colleagues who provide their time and expertise freely and generously. I would also like to thank ASHM for their ongoing support including operational and organisational services, conference support and education services.

While the next 12 months continues to present challenges, our collective experience over the recent period has demonstrated the importance of global connection and collaboration. While we need to be creative and adaptive to how we do our work, the need to foster and nurture networks like INHSU has never been more important.

We thank you for your ongoing involvement in our community.

Board of directors



Jason Grebely, INHSU
PRESIDENT, THE KIRBY INSTITUTE,
UNSW, AUSTRALIA

Professor Jason Grebely is the Head of the Hepatitis C and Drug Use Research Group in the Viral Hepatitis Clinical Research Program, Kirby Institute at UNSW Sydney in Australia. Professor Grebely's research focuses on the epidemiology, testing, and treatment for hepatitis C infection, with a particular focus on people who inject drugs. He also conducts research to understand harms that may be related to drug use and interventions to address these harms. He is a Senior Editor for the International Journal of Drug Policy.



Julie Bruneau, INHSU VICE
PRESIDENT/SECRETARY,
UNIVERSITY OF MONTREAL,
CANADA

Julie is Professor in the Department of Family and Emergency Medicine at Université de Montréal. She is Head of the Primary Care Department at the Centre Hospitalier de l'Université de Montréal (CHUM). Her research focusses on factors impeding and facilitating harm reduction efforts (such as syringe exchange and Opioid Agonist Therapy (OAT)) among persons who inject drugs.



Jude Byrne, AUSTRALIAN
INJECTING AND ILLICIT DRUG
USERS LEAGUE (AIVL), AUSTRALIA

Jude has over three decades working in peer-based drug user organisations developing and implementing education campaigns and materials on HCV prevention, testing and treatment for the injecting community. Jude has represented the HCV-related needs of the injecting drug using community on local, national and international committees and works with researchers to help target and appropriately interact with community.



Erika Castro, HEPC VIRTUAL
CLINIC, SWITZERLAND

Erika is an internal and addiction medicine specialist based in downtown Lausanne. Her clinical practice concerns people who use drugs and alcohol as well as chemsex users. She leads a hepatitis C microelimination network in her region. She participates to the Swiss cohort Study for the Medical Management of Substance Users (SAMMSU) and chairs various addiction medicine education initiatives in Switzerland. She's also a trainer of the UNODC TreatNet program.



Margaret Hellard, BURNET INSTITUTE, AUSTRALIA

Margaret is Deputy Director (Programs) at the Burnet Institute, Head of Hepatitis Services in the Department of Infectious Disease at The Alfred Hospital and an Adjunct Professor of Infectious Diseases Epidemiology at Monash University in Melbourne, Australia. Margaret is Co-Chair of the WHO Strategic and Technical Advisory Committee on HIV and Viral Hepatitis.



Matt Hickman, UNIVERSITY OF BRISTOL, UNITED KINGDOM

Matt is Professor in Public Health and Epidemiology, NIHR Senior Investigator, Head of Population Sciences and Deputy Head of Bristol Medical School at University of Bristol. He is Director of National Institute Health Research (NIHR) Health Protection Research Unit on Behavioural Science and Evaluation and co-PI of NIHR Programme grant EPIToPe (Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs).



Alain Litwin, INHSU VICE PRESIDENT/SECRETARY, MONTEFIORE MEDICAL CENTER, UNITED STATES OF AMERICA

Alain is vice chair of academics and research at Prisma Health, executive director of the Addiction Research Center at the Health Sciences Center, and professor of medicine at the University of South Carolina School of Medicine–Greenville and the Clemson University School of Health Research. Dr. Litwin's research focuses on developing and evaluating models of HCV, addiction, and medical care for people who inject drugs.



Natasha K. Martin, INHSU TREASURER, UNIVERSITY OF CALIFORNIA SAN DIEGO, UNITED STATES OF AMERICA

Natasha is an Associate Professor in the Division of Infectious Diseases and Global Public Health in the Department of Medicine at the University of California San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Her work evaluates the impact and cost-effectiveness of viral hepatitis and HIV prevention interventions among high risk populations.



Håvard Midgard, OSLO
UNIVERSITY HOSPITAL, NORWAY

Håvard is a specialist in internal medicine and gastroenterology/hepatology at Oslo University Hospital, and a postdoctoral researcher at Akershus University Hospital, Norway. His research interests include HCV epidemiology and models of HCV care for people who inject drugs, as well as liver cirrhosis and its complications. He has been central in the development of the Norwegian HCV elimination strategy.



Tracy Swan, CONSULTANT,
UNITED STATES OF AMERICA

A hepatitis C activist since 1998, Tracy has worked on a range of issues including drug development and access to medicines, especially for people who use drugs, people living with HIV, and people in low and middle-income countries. She has worked for Treatment Action Group, the Medicines Sans Frontiers Access Campaign and served as a community representative to the FDA antiviral advisory committee, AIDS Clinical Trials Group, and been a member of US and WHO hepatitis C treatment guidelines panels.



Board members, INHSU staff and
delegates at INHSU 2019.

Staff

Emma Day, DIRECTOR OF PROGRAMS AND OPERATIONS

Emma leads INHSU's program strategy, funding development, execution of projects, monitoring and evaluation of program work and quality improvement processes. At the end of this reporting period, we said farewell to Emma. We wish her all the best in her new endeavors and deeply thank her for her contributions to INHSU over many years.

Michelle Kwok, PROJECT OFFICER

Michelle supports all INHSU activities, including project delivery and organisation operations.

Rebecca Vassarotti, DIRECTOR OF STRATEGY AND POLICY

Rebecca leads INHSU's strategic planning, policy and advocacy work. Her expertise covers governance, strategic planning, organisational and policy development, advocacy, evaluation and community development.

We are delighted to welcome Nikitah Habraken as Program Manager and Brooke Nolan as Senior Marketing and Communications Officer to the staff team at the beginning of 2020/2021.

Our members



Our members are core to the network, and it is important that we remove any barriers to entry. To make our network more inclusive – particularly for community-based members, people from low and middle-income countries, students, nurses, allied health professionals, and trainees – we have created a new membership fee structure.

Joining INHSU as a member connects you to those who share a common interest in improving the health of people who use drugs. It transcends professional boundaries and provides an opportunity to be part of knowledge exchange and learning as well as to connect and collaborate with others.

Benefits of joining INHSU include:

- A quarterly newsletter
- Discounted rates for INHSU's annual conference
- The ability to contribute to the INHSU board and committee
- Invitations to activities/events



896
members




51
countries
represented



29
INHSU Prisons
members

Professional affiliation:

- Practitioner
- Nurse
- Researcher
- Student
- Community



Members join INHSU from clinical, research and community settings.



Community Day, INHSU 2019

INHSU Prisons and INHSU Committees



INHSU has been working to establish and support groups of interest within our membership, with **INHSU Prisons** the first formal Special Interest Group of the network.

Operating throughout 2019/2020, INHSU Prisons is led by Professor Andrew Lloyd and Yumi Sheehan from the Kirby Institute at UNSW Sydney. We thank them for their tireless dedication and hard work. It has been a busy first year, with the Executive working on a range of proposals and activities to develop education and advocacy tools to improve access to hepatitis treatment and care within prison systems across the globe.

- A successful pre-conference workshop for 100 people at INHSU's annual conference in 2019
- Participation in INHSU Africa 2020, with INHSU Prisons now working on building the network of people in this region

The Community Committee has been established to support INHSU in delivering inclusive conference programming, including supporting the highly successful Community Day which is run in conjunction with the INHSU annual conference.

INHSU is currently exploring the potential of developing this group into a Special Interest Group and we thank Jude Byrne from the Board for her stewardship of this group.

The Early Career Researchers Committee has been established to explore how we can better support members of the network at earlier stages of their career. **Our conference has always been key in supporting emerging leaders, but there is always more to do.**

Strategic planning



This year, INHSU undertook an extensive strategic planning process to support the organisation as it moves into its second decade of operation.

This process provided an opportunity for the Board, members and stakeholders to celebrate the successes of INHSU, reflect on the challenges ahead and create a clear strategy to ensure the organisation continues to be a leading international organisation supporting better health for people who use drugs.

This extensive process included the distribution of a stakeholder survey that was completed by 150 members, partners and stakeholders, along with focus groups and many one-on-one interviews.

This process was very affirming for the organisation regarding the impact INHSU is having around its core mission and work:

- It highlighted the need for INHSU to continue to broaden its work to include improving the health of people who use drugs, beyond hepatitis prevention, treatment and care
- It confirmed that our core work around knowledge exchange, education and advocacy continue to be important
- It highlighted the need to grow this global community and invest in working in low and middle-income settings

This work has resulted in the development of a new strategic plan to be presented to the membership at the 2020 General Assembly Meeting. The new strategic plan is available via the website. A key change is the broadening of the organisation's focus to work more broadly in improving the health of people who use drugs.




Delegates during INHSU 2019, Montreal, Canada.



Montreal,
Canada

706
attendees

- Researchers
- Health Care Practitioners
- Policy Makers /Public Health
- Community
- Other



The 8th International Conference on Hepatitis Care in Substance Users

Montreal, Canada 11-13 SEPTEMBER 2019

The INHSU conference covers the latest advances on epidemiology, management and treatment of viral hepatitis among people who use drugs, with a specific focus on hepatitis C. The conference has a truly international focus attracting delegates from around the world, including health professionals (doctors, nurses and allied health), researchers, representatives from community organisations, people who use drugs and policy makers.



49
countries
represented



39
invited
speakers



5
plenary
sessions



12
proffered paper
sessions



191
posters



353
submission
abstracts



84
scholarships provided to
academics, practitioners and
community members

INHSU Africa



From 17th to 20th February 2020 in Cape Town, South Africa, INHSU hosted INHSU Africa 2020, our first-ever regional event. Almost 200 delegates from 10 African countries – alongside international partners – gathered to reflect on the key issues facing people who use drugs across Africa and strategies to respond to them.

This event was a huge success, in large part due to the contributions of a wide range of partners and supporters.

Particular thanks goes to the Australasian Society for HIV, Sexual Health and Viral Hepatitis Medicine (ASHM) and TB HIV Care who co-hosted the event. Other partners including Open Society Foundation, and Frontline AIDS enabled the participation of a wide range of delegates from across the African region.

Delegates included representatives from parliaments, governments, clinical providers, academic institutions and community-based services and advocates.

INHSU Africa included an Advocacy Day, a Policy Day conducted in partnership with UNITE and a two-day traditional conference. In association with the event, ASHM also conducted education for clinical practitioners in both Cape Town and Pretoria.

The Africa declaration to eliminate hepatitis C

A key outcome of the event was the development and endorsement of the 'Africa Declaration to eliminate hepatitis C and improve the health of people who use drugs' by 21 African and globally-based organisations. This declaration sets out the case for more action on these issues and calls on government to commit to seven actions to support more progress around hepatitis C elimination and improved health for people who use drugs.

This is just the beginning

Following the regional meeting and thanks to support from the Open Society Foundation, INHSU has been working with partners in both South Africa and Kenya to engage in ongoing work.

While this has been impacted by the COVID-19 pandemic, this crisis has also highlighted the need for us to support our work in a COVID-safe manner. Projects being supported include virtual forums to enable cross-country and cross-sector work, work to amplify advocacy efforts and projects that are exploring ways to support people who use drugs to document their experiences through the pandemic.



181
attendees



28
scholarships



2
HCV workshops
for healthcare practitioners



23
countries represented



16 Low/middle
income countries



10 African countries

Hepatitis C in primary care and drug and alcohol settings education program



The INHSU education program is a tailored, CME accredited program for practitioners in primary care and drug and alcohol clinics. The program provides practitioners with the knowledge and skills to expand hepatitis C care beyond hospital settings, supporting increased hepatitis C screening, linkage-to-care and treatment among people who use drugs.

The program uses a blended learning approach, utilising online learning, face-to-face workshops, virtual classrooms, interactive resources and decision-making tools.

In collaboration with the **Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)**, the education program has been successfully delivered in 11 countries. Content is modified to local context and tailored to regional, state/province, local health district, setting level as appropriate.

During 2019/20, INHSU launched the program in Germany, Italy and Sweden and continued program delivery in Canada, France and Switzerland. We are deeply grateful to local steering committees, partners, sponsors and program attendees for their engagement and support of the program.



419
people trained



24
workshops



06
in Canada



05
in France



01
in Germany



05
in Italy




03
in Sweden



04
in Switzerland

Professional affiliation:

- Physician (GPs, specialised physicians)
- Nurse
- Allied Health
- Other (educator, management)



Advocacy efforts



INHSU is committed to working with international organisations and partners to progress and support our aim to improve the health of people who use drugs. **The ultimate aim is to ensure that global agreements to eliminate viral hepatitis by 2030** are supported by evidence-based policy, resources and person-centred implementation.

Throughout 2019/2020, INHSU was delighted to partner with a wide range of organisations on a variety of activities to pursue these aims.

A global reach

INHSU Africa 2020 resulted in 22 organisations supporting the Africa Declaration, calling on regional governments to support evidence-based policy in this area.

The INHSU Africa 2020 Policy Day, held in association with UNITE, proved the power of creating a space for advocates, decision makers and policy makers to develop a common agenda of action. We will continue to support this work.

We have also worked with partners in the provision of workshops and sessions at international conferences and networks including the 2019 Lisbon Addictions Conference.



The Know Your Status program run at the Ahtahkakoop Health Centre. Image taken as part of Connecting with Care Canada project.

Connecting With Care

While evidence is at the heart of our policy work, we also recognise the importance of ensuring the voices of people drive the advocacy effort. The Connecting with Care project has been an important way in which INHSU has supported these efforts.

Connecting with Care is a new INHSU initiative that uses storytelling and education to profile good practice and innovative models of care for hepatitis C elimination and improving the health of people who use drugs.

Connecting with Care aims to address INHSU's strategic objectives of knowledge dissemination, education, and policy and advocacy.

The project aims to:

- **Inspire** community organisations, practitioners, advocates and policy makers by showcasing emerging and innovative practice
- **Educate** these groups through providing tools and resources that facilitate good practice.



Delegates from INHSU Africa 2020 at the Policy Day.

Advocacy efforts



Award-winning storytelling

This project began with a focus on digital storytelling, with three films being produced in Canada profiling work in [Ahtahkakoop](#), [Montreal](#) and [Toronto](#).

These were delivered in partnership with our Canadian partners CATIE and CanHepC, and in association with the film maker Conor Ashleigh.

We also produced a digital story 'Connecting with Care South Africa' with Conor Ashleigh and partners TB HIV Care and the South African Network of People who Use Drugs (SANPUD).

We were humbled and excited by the news that Connecting with Care Ahtahkakoop was awarded the overall grand prize at the Global Hepatitis Elimination Film Awards.

[Connecting with Care South Africa](#) was awarded first prize in the Political and Civil Support category and Connecting with Care Montreal and Connecting with Care Toronto were given honourable mentions. The prize money rewarded in these wins will be invested back into the communities profiled in the films.

2019/2020 financial report

International Network on Hepatitis in Substance Users INHSU, Zürich

BALANCE SHEET AS AT JUNE 30, 2020

(with 2019 comparative figures)

	Notes	30.06.2020 EUR	30.06.2019 EUR	30.06.2020 CHF	30.06.2019 CHF
ASSETS					
Cash and cash equivalents	3.1.	298'463	244'165	318'102	279'838
Trade receivables		5'000	55'212	5'329	63'278
Other receivables	3.2.	30'009	30'009	31'984	34'393
Prepaid expenses	3.3.	4'223	573	4'501	657
Work in progress	3.4.	33'752	–	35'973	–
Total current assets		371'447	329'959	395'889	378'166
Total assets		371'447	329'959	395'889	378'166
LIABILITIES					
Trade creditors		53'333	55'956	56'843	64'131
Deferred income and accrued expenses	3.5.	20'175	4'700	21'503	5'387
Total current borrowed capital		73'508	60'656	78'346	69'518
Balance carried forward		269'303	157'749	308'648	189'536
Profit of the period		28'636	111'554	8'895	119'112
Total net assets		279'939	269'303	317'543	308'648
Total liabilities		371'447	329'959	395'889	378'166

The accompanying notes are an integral part of these financial statements

PREVIOUS / NEXT

2019/2020 financial report

International Network on Hepatitis in Substance Users INHSU, Zürich PROFIT AND LOSS ACCOUNT FOR THE PERIOD ENDED JUNE 30, 2020 (with 2019 comparative figures)

	Notes	From 01.07.2019 to 30.06.2020 EUR	From 01.07.2018 to 30.06.2019 EUR	From 01.07.2019 to 30.06.2020 CHF	From 01.07.2018 30.06.2019 CHF
Conference fees	3.9.	698'954	–	765'943	–
Membership fees		7'275	15'830	7'972	18'207
Management fees		25'519	16'325	27'965	18'776
Sponsorship fees		548'307	979'657	600'858	1'126'744
Surplus of conferences	3.9.	–	163'753	–	188'339
Surplus of education programs		63'609	–	69'705	–
Other income		4'514	–	4'947	–
Total operating income		1'348'178	1'175'565	1'477'390	1'352'066
Operating expenses					
Administration expenses	3.6.	45'638	47'142	50'012	54'220
Other operating expenses	3.7.	493'935	979'654	541'275	1'126'741
Staff costs	3.8.	148'049	36'707	162'238	42'218
Conference expenses	3.9.	623'993	–	683'798	–
Total operating expenses		1'311'615	1'063'503	1'437'323	1'223'179
Operating profit		36'563	112'062	40'067	128'887
Financial income / (costs)					
Exchange rate, net loss		(7'541)	(210)	(8'264)	(242)
Financial costs		(386)	(298)	(423)	(343)
Total financial income / (costs)		(7'927)	(508)	(8'687)	(585)
Currency translation adjustment		–	–	(22'485)	(9'190)
Profit of the period		28'636	111'554	8'895	119'112

The accompanying notes are an integral part of these financial statements

2019/2020 financial report

International Network on Hepatitis in Substance Users INHSU, Zürich NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2020

1. General information

International Network on Hepatitis in Substance Users (INHSU), Zurich is an Association (so called "Verein" under Swiss Code of Obligation) established on October 20, 2010 and registered in the Swiss Register of Commerce on December 17, 2010 with the purpose to improve the knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care with people who use drugs. In particular the Association aims to support and facilitates scientific exchange and dissemination of knowledge among specialists, strives to educate international health professionals, researchers, community organisations, people who use drugs and policy makers on hepatitis C prevention, screening, linkage to care, and treatment among people who use drugs and seeks to collaborate with other societies, government organisations, professional associations, community members, institutions and individuals to advocate for hepatitis C prevention and care among people who use drugs.

The Association is established in Schützengasse 31, 8001 Zurich, Switzerland.

2. Key accounting and valuation principles

These financial statements have been prepared in accordance with the requirements of Swiss law (Swiss Code of Obligations) and the articles of incorporation.

The main accounting and valuation principles used are described as follows.

Functional currency and conversion of the financial statements

The Association's functional and presentation currency is EUR.

Consequently, as required by Swiss law, these financial statements present also the comparative figures in CHF under the following rules:

- Equity: historical exchange rate;
- Balance sheet: closing exchange rate at June 30, 2020 of EUR/CHF 1.0658 (June 30, 2019: EUR/CHF 1.14610);
- Profit and Loss account: average exchange rate of the period July 1, 2019 - June 30, 2020 of EUR/CHF 1.0958 (July 1, 2018 - June 30, 2019: EUR/CHF 1.1501).

Conversions of foreign currency items

Transactions in foreign currencies are converted in EUR at the exchange rate on the day the transaction takes place.

Monetary assets and liabilities denominated in foreign currencies are converted into EUR accounts at the exchange rate on the balance sheet date. Any profits or losses resulting from the conversion are recorded in the profit and loss account.

Non-monetary assets and liabilities in foreign currencies are converted at the foreign exchange rate at the time of the transaction. Any foreign exchange profits resulting from the conversion at the exchange rate on the balance sheet date are deferred in the balance sheet whereas exchange losses are recorded in the profit and loss account.

Cash and cash equivalents

Cash and cash equivalents are recorded at their nominal value.

Trade receivables and Other receivables

Trade receivables and Other receivables are presented at their nominal value.

If a debtor is considered unlikely to be able to pay the debt, a value adjustment is made.

Prepaid expenses and accrued income

Prepaid expenses and accrued income are recorded at their nominal value.

2019/2020 financial report

International Network on Hepatitis in Substance Users INHSU, Zürich NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2020

Trade creditors and Other liabilities

Trade creditors and Other liabilities are recorded at their nominal value.

Deferred income and accrued expenses

Accrued expenses are recorded at their nominal value.

Taxes

According to the Swiss tax authorities the Association is tax-exempt.

Revenue recognition

The Association finances its activities through annual membership fees, sponsorship fees and conferences.

3. Information relating to items on the balance sheet and profit and loss account

3.1. Cash and cash equivalents

The item includes bank account balances for EUR 298,463, equivalent to CHF 318,102 as at June 30, 2020 (June 30, 2019: EUR 244,165 equivalent to CHF 279,838).

3.2. Other receivables

The caption, amounting to EUR 30,009 equivalent to CHF 31,984 as at June 30, 2020, relates to receivables for conference seed funding (June 30, 2019: EUR 30,009 equivalent to CHF 34,393).

3.3. Prepaid expenses

Prepaid expenses amounting to EUR 4,223 equivalent to CHF 4,501 as at June 30, 2020 (June 30, 2019: EUR 573 equivalent to CHF 657) mainly relate to amounts paid in advance for insurances.

3.4. Work in progress

The caption represents a timing difference between income received on INHSU's Connecting with Care project and monies paid to ASHM to enable it to manage this project and pay the service providers required.

3.5. Deferred income and accrued expenses

This caption can be split as follows:

	30.06.2020 EUR	30.06.2019 EUR	30.06.2020 CHF	30.06.2019 CHF
Deferred income	16'175	-	17'239	-
Accrued expenses	4'000	4'700	4'263	5'387
Total deferred income and accrued expenses	20'175	4'700	21'503	5'387

2019/2020 financial report

International Network on Hepatitis in Substance Users INHSU, Zürich

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2020

3.6. Administration expenses

This caption can be split as follows:

	From 01.07.2019 to 30.06.2020 EUR	From 01.07.2018 to 30.06.2019 EUR	From 01.07.2019 to 30.06.2020 CHF	From 01.07.2018 to 30.06.2019 CHF
Governance and planning	7'412	11'220	8'122	12'905
Bookkeeping and financial management	6'889	7'920	7'549	9'109
Website maintenance	1'899	3'032	2'081	3'487
Membership administration	–	4'839	–	5'566
Insurance expenses	2'467	6'463	2'703	7'433
Consulting & Professional service fees	5'279	5'825	5'785	6'700
Travel and accommodation expenses	13'223	2'553	14'490	2'936
Various expenses	8'469	5'290	9'281	6'084
Total administration expenses	45'638	47'142	50'012	54'220

3.7. Other operating expenses

The caption, amounting to EUR 493,935 equivalent to CHF 541,275 as at June 30, 2020 (June 30, 2019: EUR 979,654 equivalent to CHF 1,126,741) mainly relates to expenses for the funding of INHSU projects.

3.8. Staff costs

ASHM engages 3 part-time employees (June 30, 2019: 1) on behalf of INHSU to work on INHSU strategy and operational matters. Whilst the related employment costs have been recorded as Staff Costs in this Financial Report, the employee's contract is V>lith ASHM and is subject to Australian workplace law.

3.9. Conference fees and expenses

INHSU engages ASHM to manage its annual conference. In previous years, INHSU has only accounted for the surplus on its conference, as remitted by ASHM. This year, INHSU management, after consultation with its auditor, have decided to account for the gross conference income and expenses to provide a more representative picture of INHSU's activities. It was also decided not to restate the prior year profit and loss for this change.

The caption of the revenues for the conference fees can be split as follows:

	From 01.07.2019 to 30.06.2020 EUR	From 01.07.2019 to 30.06.2020 CHF
Conference other	24'335	26'667
Conference Registrations	317'524	347'956
Conference Sponsorship	357'095	391'320
Total administration expenses	698'954	765'943

2019/2020 financial report

Independent auditor's report to the members of International Network on Hepatitis in Substance Users (INHSU), Zurich

I have audited the statutory financial statements of INHSU which comprise:

- the balance sheet as at June 30, 2020
- the profit and loss account for the period ended June 30, 2020
- the notes to the financial statements for the year ended June 30, 2020

In my opinion, the statutory financial statements of INHSU:

- give a true and fair view of the state of IN HSU' s affairs as of June 30, 2020 and of its profit of the period ended June 30, 2020
- have been properly prepared in accordance with Swiss GAAP.



Dipl. Oec. Christa Berchtold (auditor)

DE- 78239 Rielasingen

Zurich, September 4, 2020

Thank you



www.inhsu.org